-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical’s Innovation Consortium Has Been Recognized as a Provincial-Level Innovation Consortium
Category:
发布时间：2024-12-11
【概要描述】
On December 9, the Hebei Provincial Department of Science and Technology announced the second batch of provincial-level innovation consortia for 2024, with Shijiazhuang Sihua Pharmaceutical Co., Ltd.’s Hebei Provincial Liquid Sterile Preparations Innovation Consortium successfully selected.
On December 9, the Hebei Provincial Department of Science and Technology announced the second batch of provincial-level innovation consortia for 2024, with Shijiazhuang Sihua Pharmaceutical Co., Ltd.’s Hebei Provincial Liquid Sterile Preparations Innovation Consortium successfully selected.
In accordance with the relevant provisions of the “Guidelines for the Establishment of Innovation Consortia in Hebei Province” and the “Notice on Further Advancing the Formation of Innovation Consortia in Hebei Province,” and following expert evaluation, the Hebei Provincial Department of Science and Technology has designated the second batch of provincial-level innovation consortia for 2024, comprising a total of four enterprise consortia, two of which are based in Shijiazhuang.
As a leading enterprise in the large-volume parenteral solutions industry, Shijiazhuang Sihua Pharmaceutical aligns its strategic vision with national priorities and market demands, focusing on fundamental, innovative, and forward-looking research and industrialization of its core product line—large-volume parenteral solutions. The company has established deep industry–university–research–application collaborations with renowned universities and research institutes, including China Pharmaceutical University, Shenyang Pharmaceutical University, Lanzhou University, and Hebei Medical University. By synergistically leveraging innovation and talent networks, Shijiazhuang Sihua has built a high-performance, innovation-driven ecosystem for integrated development spanning both active pharmaceutical ingredients and finished dosage forms. As a result, innovative application scenarios continue to expand, and the company’s innovation influence and market competitiveness have achieved a new leap forward.
According to reports, the Hebei Provincial Innovation Consortium is a deep-integrated industry–academia–research–application innovation organization led by a leading enterprise in the industry, bringing together key enterprises across the industrial chain—both upstream and downstream—as well as universities, research institutions, relevant science-and-technology service agencies, and social organizations. Driven by market mechanisms, bound by shared interests, and underpinned by mutually agreed contracts, this consortium serves as an effective organizational model for leveraging the primary role of enterprises in technological innovation, pooling innovative resources from all sectors, accelerating breakthroughs in critical core technologies, promoting the commercialization of scientific and technological achievements, and fostering the deep integration of industrial and innovation chains.
The Group’s head of R&D stated that the organization will fully leverage the long-term cooperative mechanism and its associated benefits—namely, complementary strengths among members of the innovation consortium, collaborative innovation, shared interests, and shared risk—to actively facilitate the alignment of scientific and technological achievements, accelerate breakthroughs in key technologies, promote the translation of cutting-edge scientific and technological advances into real-world productive forces, continuously advance the development of the innovation consortium, and steadily enhance the company’s core competitiveness. Through these innovative efforts that deliver tangible results, the Group is committed to making new contributions and assuming new responsibilities in driving the city’s biopharmaceutical industry forward.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091